Search Criteria: Research Area is "Internal/Organ Research: Kidney Defects (polycystic kidney disease)"

New Strains Under Development

JAX^® Mice Strains

Stock Number	Strain Name   Strain Description	Standard Supply
004525	B6.129S1-Bcl2l11tm1.1Ast/J	Repository- Live
	Mice that are homozygous for the targeted mutation are viable, normal in size and do not display any gross physical or behavioral abnormalities. No full length gene product (protein) is immunodetected in spleen cells from homozygous mutant mice. Homozygous mice have lympho-myeloid hyperplasia and reduced platelet number. Lymphocytes are insensitive to certain apoptotic stimuli. Both homozygous and heterozygous mice exhibit progressive systemic autoimmune disease. This mutant mouse strain may be useful in studies of apoptosis, degenerative and autoimmune diseases, including lupus erythematosus and autoimmune kidney disease.
003082	129S1/SvImJ-Bcl2tm1Mpin/J	Repository-Cryopreserved
	Heterozygous mice exhibit expression of beta-galactosidase in populations of large sensory neurons. Mice homozygous for the Bcl2tm1Mpin targeted mutation do not produce either the a or b form of the Bcl2 protein. Bcl2 is a major regulator of programmed cell death, a critical process in shaping the developing nervous system. The absence of the Bcl2 does not significantly influence the development of motor neurons before or during the main period of physiological cell death. Rather, Bcl2 exerts its influence beyond this period, subsequent to the phase where the majority of neuronal loss normally takes place. Polycystic kidney disease is less severe in this strain compared to the Bcl2tm1Sjk targeted mutation (Stock No. 002265).
000152	B6(Cg)-Cys1cpk/J	Repository-Cryopreserved
002265	B6;129S2-Bcl2tm1Sjk/J	Repository-Cryopreserved
	Mice homozygous for the Bcl2tm1Sjk targeted mutation appear normal at birth; however, growth retardation is evident by one week of age with considerable heterogeneity in weight compared to normal wildtype siblings (30% to 90%). There is some pre-weaning loss. Homozygotes succumb to renal failure as a result of polycystic kidney disease. Hematopoiesis, including lymphocyte differentiation is initially normal but the thymus and spleen decrease in size due to increased apoptosis. The coat color of homozygotes turns grey with the second hair follicle cycle.
007555	B6SJL-Bicc1tm1Emdr/J	Repository-Cryopreserved
	Homozygous mutants survive a few weeks after birth, but display polycystic kidney disease. LacZ expression was observed in the Henson's node at embryonic day 7.5 and in the endoderm of the gut at embryonic day 8.5

(5 stocks)         Back to Top

New Strains Under Development

(See informational text following listing of strains)

How to Register Interest
Please indicate your interest in purchasing any of the strains listed below when they become available for distribution by checking the box next to the strain(s) of interest and then selecting the "Continue" button which leads to an Interest Form.

View a Data sheet for New Strains Under Development
Select the strain name to link to the strain data sheet.

	Stock Number	Strain Name   Strain Description	Standard Supply
	007176	B6.Cg-Tg(Pax8-rtTA2S*M2)1Koes/J	Under Development for Production
	Transgenic Pax8-rtTA mice are viable and fertile. These mice express an optimized reverse tetracycline-controlled transactivator (rtTA2S-M2) protein under the control of the murine Pax8 promoter, which directs expression to proximal and distal tubules and the collecting duct system of both embryonic and adult kidney. The rtTA2S-M2 variant of rtTA contains five amino acid changes in the TetR moiety (S12G, E19G, A56P, D148E, and H179R) and a synthetic optimized transactivating domain, resulting in reduced basal activity and enhanced doxycycline sensitivity compared to wild-type rtTA. When mated to a second strain carrying a gene of interest under the regulatory control of a tetracycline-responsive promoter element (TRE or tetO), expression of the target gene in kidney cells is induced with administration of the tetracycline analog, doxycycline (dox). These Pax8-rtTA mice provide a Tet-On tool that allows the inducible expression of genes in renal tubular epithelial ..... For more information please see the full description on the strain data sheet

(1 stocks)         Back to Top

New Strains Under Development

• Receive periodic updates on the status of the colony UNDER DEVELOPMENT
• Obtain advance notification of strain availability and opportunity to order prior to the strain being published as available
• Provide input affecting speed and quantity of availability

The Jackson Laboratory serves as a worldwide distributor and national repository for common and rare strains of inbred mice and mice carrying spontaneous mutations or induced mutations (i.e., transgenic, targeted/"knockout", or chemically induced mutations). At any one time, we have over 100 strains at various stages of development and colony expansion. Strains "Under Development" fall into two categories depending on the anticipated demand from the scientific community.

1. Strains that will be made available from a live distribution colony at The Jackson Laboratory.
   These strains are designated as: "Under Development for Distribution Colony"
2. Strains that will be made available through the Cryopreservation Repository.
   These strains are designated as: "Under Development for Cryopreservation Repository"

It is VERY IMPORTANT that you register interest in strains Under Development. The anticipated demand for a strain enables us to determine effectively the distribution plan for each strain Under Development. Registering interest also provides benefits to you (including advance notification of pending availability). Whether a strain is made available from a live colony OR from our cryopreservation repository, you may want to consider the option of Dedicated Supply. To learn more about Dedicated Supply, go to Services.

Back to top

Send questions to our Technical Support team using the Express Technical Support Form.
(3.2)